Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections.

MLA

Warner, Nathaniel C., et al. “Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter Xylosoxidans Infections.” Clinical Infectious Diseases, vol. 73, no. 7, Oct. 2021, pp. e1754–57. EBSCOhost, https://doi.org/10.1093/cid/ciaa1847.

APA

Warner, N. C., Bartelt, L. A., Lachiewicz, A. M., Tompkins, K. M., Miller, M. B., Alby, K., Jones, M. B., Carr, A. L., Alexander, J., Gainey, A. B., Daniels, R., Burch, A.-K., Brown, D. E., Brownstein, M. J., Cheema, F., Linder, K. E., Shields, R. K., Longworth, S., & Duin, D. van. (2021). Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections. Clinical Infectious Diseases, 73(7), e1754–e1757. https://doi.org/10.1093/cid/ciaa1847

Chicago

Warner, Nathaniel C, Luther A Bartelt, Anne M Lachiewicz, Kathleen M Tompkins, Melissa B Miller, Kevin Alby, Melissa B Jones, et al. 2021. “Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter Xylosoxidans Infections.” Clinical Infectious Diseases 73 (7): e1754–57. doi:10.1093/cid/ciaa1847.